Clinical trials: Aggressive Lymphoma
Relapsed/Refractory Aggressive B-Cell Lymphoma
A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies
This study is researching a combination of 2 experimental drugs, referred to as "study drugs", called odronextamab (also known as REGN1979) and cemiplimab (also known as REGN2810).
- Trial name
- CLIO-1 (NCT02651662)
- Testing
- cemiplimab, odronextamab
- Where
- 30 sites in United States, Austria and 4 more
- Volunteers
- 105 people
- Sponsor
- Regeneron Pharmaceuticals
B-cell Lymphoma, Burkitt Lymphoma
Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies
The overarching hypothesis for this study is that a safe and tolerable dose (i.e., the maximum tolerated dose) will be identified for loncastuximab tesirine in combination with dose-adjusted etoposide phosphate, prednisone…
- Trial name
- LONCA (NCT05270057)
- Testing
- Etoposide, Doxorubicin, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Medical College of Wisconsin
Mature B-cell Non-Hodgkin Lymphoma
Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents
The trial B-NHL 2013 is a collaborative prospective, multi-national, multi-center, randomized trial with participating centers of the NHL-BFM group (Austria, Switzerland, Czech Republic, Germany) and the Scandinavian NOPHO group…
- Trial name
- B-NHL 2013 (NCT03206671)
- Testing
- Rituximab window, Additional doses of Rituximab, Cyclophosphamide
- Where
- 88 sites in Austria, Czechia and 6 more
- Volunteers
- 650 people
- Sponsor
- University Hospital Muenster
B-cell Non-Hodgkin Lymphoma, Aggressive
DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
The purpose of this study is to determine whether a blood test can accurately detect whether if the participant's lymphoma has come back after completion of initial chemotherapy treatment for their aggressive B-cell Non-Hodgkin…
- Trial name
- NCT02633111
- Testing
- collected at pre-treatment tumor biopsy, Peripheral blood tests, PET/CT
- Where
- 12 sites in United States
- Volunteers
- 501 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Extranodal NK/T-cell Lymphoma, Aggressive NK-Cell Leukemia
Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases
This is a multicenter, non-interventional, ambidirectional cohort study of Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases.
- Conditions
- Extranodal NK/T-cell Lymphoma, Aggressive NK-Cell Leukemia, Systemic Chronic Active Epstein-Barr Virus Disease, Epstein-Barr Virus-Positive Nodal T/NK-Cell Lymphoma
- Trial name
- EBV-T/NK Cohor (NCT07727083)
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Rong Tao
Non-Hodgkin's Lymphoma
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide
The Phase I part of the study will apply to identify dose-limiting toxicities (DLT) and to define maximum-tolerated dose (MTD) for a new chemoimmunotherapy combination of bendamustine, ofatumumab, carboplatin, and etoposide in…
- Trial name
- NCT01458366
- Testing
- Bendamustine, Ofatumumab, Carboplatin
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Lymphoma, Non-Hodgkin
Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology
This is a single-arm, open-label study of Iodine 131 Anti B1 Antibody for the treatment of 1st or 2nd relapsed indolent B cell lymphomas or B cell lymphomas that have transformed to a more aggressive histology.
- Trial name
- NCT00950755
- Testing
- tositumomab and Iodine I 131 tositumomab (anti-B1 antibody)
- Volunteers
- 41 people
- Sponsor
- GlaxoSmithKline
Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma
A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma
The purpose of this study is to assess the safety of SyB L-0501 in combination with Rituximab to patients with aggressive B-cell non-Hodgkin's lymphoma, and to explore the recommended dose for the Phase II clinical trial.
- Conditions
- Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT00794638
- Testing
- SyB L-0501, Rituximab
- Where
- 4 sites in Japan
- Volunteers
- 9 people
- Sponsor
- SymBio Pharmaceuticals
Follicular Lymphoma, Marginal Zone B-Cell Lymphoma
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Pre-clinical data and recently published clinical data suggest a synergistic effect between lenalidomide and dexamethasone. We hypothesize that a combination of lenalidomide-dexamethasone can overcome rituximab resistance.
- Conditions
- Follicular Lymphoma, Marginal Zone B-Cell Lymphoma, MALT Lymphoma, Lymphoma of Mucosa-Associated Lymphoid Tissue
- Trial name
- NCT00783367
- Testing
- Lenalidomide, Dexamethasone, Rituximab
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
B-Cell Lymphomas
Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen
This study is a retrospective analysis of an homogeneous population of patients with aggressive B-cell lymphoma and treated upfront with R-CHOP or R-CHOP like regimens to reassess the prognostic factors and hopefully to identify…
- Trial name
- ProDLBCL (NCT01478269)
- Where
- 39 sites in Brazil, Italy
- Volunteers
- 1,927 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Non-Hodgkin Lymphoma, B-cell
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
The goal of the study is to assess the safety and anti-lymphoma activity of MEN1703 (Dapolsertib hydrochloride) when given as a single-agent or combined with glofitamab to patients with relapsed/refractory (R/R) aggressive B-cell…
- Trial name
- JASPIS-01 (NCT06534437)
- Testing
- MEN1703, Glofitamab
- Where
- 35 sites in France, Poland and 2 more
- Volunteers
- 178 people
- Sponsor
- Ryvu Therapeutics SA
DLBCL - Diffuse Large B Cell Lymphoma
Health-Related Quality of Life Outcomes in Patients With Aggressive B-Cell Lymphomas Treated With CAR-T Cell Therapy in Real Life
This study will ultimately aim at providing the scientific community with patient-reported health status data that will contribute facilitate decision-makings.
- Trial name
- LNH012 (NCT06026644)
- Where
- 13 sites in Italy
- Volunteers
- 170 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Lymphoma
Application of Telemedicine to the Management of Aggressive Lymphomas
The purpose of this study is to evaluate the value of AMA in a comparative multicenter regional study as a reference for aggressive lymphoma. The primary endpoint will be RDI.
- Trial name
- AMA (NCT03336138)
- Testing
- AMA (Assistance for ambulatory patients)
- Where
- 10 sites in France
- Volunteers
- 350 people
- Sponsor
- University Hospital, Toulouse
Diffuse Large B-cell Lymphoma, de Novo DLBCL
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
The purpose of this study is to evaluate the efficacy of Pixantrone + Rituximab compared to Gemcitabine + Rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), or follicular grade 3 lymphoma.
- Conditions
- Diffuse Large B-cell Lymphoma, de Novo DLBCL, DLBCL Transformed From Indolent Lymphoma, Follicular Grade 3 Lymphoma
- Trial name
- PIX-R (NCT01321541)
- Testing
- Pixantrone + Rituximab, Gemcitabine + Rituximab
- Where
- 131 sites in United States, Austria and 15 more
- Volunteers
- 312 people
- Sponsor
- CTI BioPharma
Lymphoma, Histiocytic Sarcoma
Pembrolizumab in Neoplasms or Lymphomas
This research study is studying a drug called pembrolizumab as a possible treatment for aggressive lymphoma or a histiocyte or dendritic cell neoplasm. The drug involved in this study is: -Pembrolizumab
- Conditions
- Lymphoma, Histiocytic Sarcoma, Follicular Dendritic Cell Sarcoma, Interdigitating Dendritic Cell Sarcoma
- Trial name
- NCT03316573
- Testing
- Pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Dana-Farber Cancer Institute
Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy
This study characterizes cardiac events following standard of care chimeric antigen receptor T cell therapy in patients with aggressive B-Cell Lymphoma that has come back (relapsed) or does not respond to treatment (refractory).
- Conditions
- Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Trial name
- NCT04870853
- Testing
- Electronic Health Record Review
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma, Non-Hodgkin
Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma
The purpose of this study is to evaluate the efficacy and safety of JCAR017 in participants with aggressive B-cell non-Hodgkin lymphoma (B-NHL)
- Trial name
- TRANSCENDWORLD (NCT03484702)
- Testing
- JCAR017
- Where
- 20 sites in Austria, Belgium and 9 more
- Volunteers
- 113 people
- Sponsor
- Celgene
Lymphoma
Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)
RATIONALE: BI 2536 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of BI 2536 in treating patients with refractory…
- Trial name
- NCT00243087
- Testing
- BI 2536
- Where
- 4 sites in United States
- Volunteers
- 41 people
- Sponsor
- Boehringer Ingelheim
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
This study is designed to assess the safety, pharmacokinetics, drug-drug interactions, and determine the recommended Phase 2 doses of co administered Duvelisib and Venetoclax in participants with relapsed or refractory chronic…
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin Lymphoma
- Trial name
- NCT02640833
- Testing
- Duvelisib, Venetoclax
- Where
- 10 sites in United States
- Sponsor
- AbbVie
Aggressive Lymphoma
Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma
Bendamustine is a well tolerable and very active agent in the treatment of Non Hodgkin's lymphoma. However, in particular in aggressive B-cell lymphoma, only very few, small studies have investigated the role of bendamustine in…
- Trial name
- B-R-ENDA (NCT01686321)
- Testing
- Bendamustine and subcutaneous rituximab
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- University of Göttingen